Edward Kim, MD

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Shifting their focus to the REFLECT trial of lenvatinib in unresectable hepatocellular carcinoma, panelists consider use of tyrosine kinase inhibition in this setting.

A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.

A brief discussion on the potential role for adjuvant therapy in patients with hepatocellular carcinoma.

Taking recent clinical trial data into account, panelists consider the best treatment option for a patient with metastatic hepatocellular carcinoma.

In the context of metastatic hepatocellular carcinoma, panelists reflect on the value of multidisciplinary care at their institutions.

After introducing the third case, a patient with metastatic hepatocellular carcinoma, experts share their perspectives on the optimal diagnosis and work-up of advanced disease.

Moving on to the second case, the panel reviews optimal treatment strategies for a 74-year-old woman with solitary hepatocellular carcinoma <3 cm and a history of cirrhosis

Panelists discuss real-world experience with Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma and highlight practical advice.

Shared insight on the results of the LEGACY study, which utilized Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma.

Centered on the patient case of solitary hepatocellular carcinoma, panelists consider the combination of locoregional and systemic therapies to improve outcomes.

Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.

Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC).